Lead sponsor
ACADIA Pharmaceuticals Inc.
8 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
8
Trials led
4
Ongoing
2,895
Total enrollment
363
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 2
4
Phase 2/3
1
Phase 3
3
Trials by status
By invitation
2
Recruiting
2
Completed
3
Terminated
1
Trials led
TrialEligibility highlightPhaseStatusEnrollment
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension StudyStudy partner/caregiver requiredPh 3By invitation752
Relapse Prevention Study of Pimavanserin in Dementia-related PsychosisMultiple dementia etiologiesPh 3Completed392
A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease PsychosisAlzheimer's diseasePh 2Completed181
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia PsychosisParkinson's disease dementiaPh 2Recruiting180
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia PsychosisStudy partner/caregiver requiredPh 3By invitation126
Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)Alzheimer's diseasePh 2Terminated111
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's DiseaseStudy partner/caregiver requiredPh 2Completed79